FDA Speeds Up Approvals for Lab Test Devices
Published Date: 5/1/2026
Notice
Summary
The FDA wants to make it easier for some medical devices used in toxicology tests by removing the need for a special pre-approval process. This change could speed up how these devices get to market and might save money for makers and users. The FDA is asking for your thoughts by June 30, 2026, before making a final decision.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
510(k) Exemption for Toxicology Tests
FDA intends to exempt certain Class II clinical toxicology test system devices from the 510(k) premarket notification when they are intended for Federal drug testing programs. If finalized, regulated industry will no longer need to submit 510(k) submissions for those listed devices, reducing the time and private costs businesses now spend preparing 510(k)s.
Exemptions Subject to Limits and Labeling
Even if exempted from 510(k), these devices remain subject to the general limitations in 21 CFR 862.9 and the proposed partial limitation that the test system be intended for employment and insurance testing and include labeling stating it is intended solely for employment and insurance testing. Manufacturers must still submit a 510(k) before marketing if a device exceeds those limitations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-08496, Agency Information Collection Activities: Proposed Collection; Comment Request
SAMHSA is updating the annual report form for the PATH program, which helps states and territories support people transitioning from homelessness. This change affects all PATH grant recipients and aims to make reporting clearer and easier, without adding extra costs or time. Comments are open now, so stakeholders can share ideas before the January 31 deadline for submitting reports.
Next: 2026-08500, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of new filings from energy companies like solar farms and power plants. These filings include status updates, tariff changes, and complaints that could affect energy rates and operations soon. If you’re involved in energy or just curious, keep an eye on deadlines for comments mostly due by mid-May 2026.